Approximately 70% of patients with breast cancer (BC) worldwide belong to the luminal subtype, including the hormone receptor (HR) [estrogen receptor (ER) and/or progesterone receptor (PgR)]-positive (HR+) and human epidermal growth factor (HER2)-negative (HER2−) subtypes [1, 2]. This evidence concerns the gene HR and breast cancer.